These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30928532)

  • 81. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Chen BA; Mackline H; Riddler SA; Cohn SE; Darin KM; Achilles SL; Scarsi KK
    AIDS; 2017 Sep; 31(14):1965-1972. PubMed ID: 28692531
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
    Ragazini CS; Bahamondes MV; Prandini TR; Brito MB; Amaral E; Bahamondes L; Duarte G; Quintana SM; Ferriani RA; Vieira CS
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):285-9. PubMed ID: 27227739
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Hormonal contraceptives for contraception in overweight or obese women.
    Lopez LM; Bernholc A; Chen M; Grey TW; Otterness C; Westhoff C; Edelman A; Helmerhorst FM
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008452. PubMed ID: 27537097
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Association of body mass index with removal of etonogestrel subdermal implant.
    Casey PM; Long ME; Marnach ML; Fleming-Harvey J; Drozdowicz LB; Weaver AL
    Contraception; 2013 Mar; 87(3):370-4. PubMed ID: 22959901
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The Etonogestrel Implant in Adolescents: Factors Associated With Removal for Bothersome Bleeding in the First Year After Insertion.
    Green S; Sheeder J; Richards M
    J Pediatr Adolesc Gynecol; 2021 Dec; 34(6):825-831. PubMed ID: 34089858
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Temporal Trends in the Uptake and Continuation of the Etonogestrel Implant in a Large Private Practice Setting.
    Howard DL; Ford A; Ceballos S; Volker KW
    J Womens Health (Larchmt); 2018 Feb; 27(2):191-195. PubMed ID: 28976797
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.
    Mascarenhas L; van Beek A; Bennink HC; Newton J
    Hum Reprod; 1998 Nov; 13(11):3057-60. PubMed ID: 9853856
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
    Lazorwitz A; Aquilante CL; Oreschak K; Sheeder J; Guiahi M; Teal S
    Obstet Gynecol; 2019 Apr; 133(4):783-794. PubMed ID: 30870275
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users.
    Mansour D; Bahamondes L; Critchley H; Darney P; Fraser IS
    Contraception; 2011 Mar; 83(3):202-10. PubMed ID: 21310280
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
    Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
    Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A life-threatening ectopic pregnancy with etonogestrel implant.
    Bouquier J; Fulda V; Bats AS; Lécuru F; Huchon C
    Contraception; 2012 Feb; 85(2):215-7. PubMed ID: 22067768
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
    Margatho D; Carvalho NM; Bahamondes L
    Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
    [No Abstract]   [Full Text] [Related]  

  • 94. Etonogestrel Implants in Adolescents: Experience, Satisfaction, and Continuation.
    Obijuru L; Bumpus S; Auinger P; Baldwin CD
    J Adolesc Health; 2016 Mar; 58(3):284-9. PubMed ID: 26903428
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Body composition and weight gain in new users of the three-monthly injectable contraceptive, depot-medroxyprogesterone acetate, after 12 months of follow-up.
    dos Santos Pde N; Modesto WO; Dal'Ava N; Bahamondes MV; Pavin EJ; Fernandes A
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):432-8. PubMed ID: 25047227
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 97. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users.
    Lazorwitz A; Sheeder J; Teal S
    Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):323-325. PubMed ID: 33596152
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Best Practices for Counseling Adolescents about the Etonogestrel Implant.
    Berlan ED; Richards MJ; Vieira CS; Creinin MD; Kaunitz AM; Fraser IS; Edelman A; Mansour D
    J Pediatr Adolesc Gynecol; 2020 Oct; 33(5):448-454. PubMed ID: 32621879
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?
    Mansour D; Fraser IS; Edelman A; Vieira CS; Kaunitz AM; Korver T; Pong A; Lin J; Shah AK; Fox M; Rekers H; Creinin MD
    Contraception; 2019 Oct; 100(4):264-268. PubMed ID: 31176688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.